secwatch.observer — SEC 8-K summary
======================================

Issuer:     SERA PROGNOSTICS, INC. (SERA)
CIK:        0001534969
Form:       8-K
Filed at:   2026-03-18T23:59:59+00:00
Accession:  0001534969-26-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sera Prognostics Q4 net loss $7.9M; PRIME study shows 56% reduction in preterm births <32 wks
--------------------------------------------------------------------------------

- Q4 2025 net loss $7.9M vs $8.6M Q4 2024; full-year net loss $31.9M vs $32.9M.
- Revenue minimal: $10k Q4, $81k full year; company remains pre-commercial.
- Cash $95.8M at Dec 31, 2025; expects to fund operations through 2028.
- PRIME study published Jan 2026: PreTRM test reduced preterm births <32 wks by 56%, NICU admissions by 20%.
- Completed $57.5M follow-on offering Feb 2025; added CMO Dr. Inglis, CCO Anderson in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534969/000153496926000008/0001534969-26-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534969/000153496926000008/sera-20260318.htm
  HTML page:      https://secwatch.observer/filing/0001534969-26-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer